Adiposs SA

Adiposs SA is a clinical-stage biotech start-up company developing medical imaging products and technologies. Today, more than 50% of cancer patients don't respond to cancer immunotherapy. They get side effects with no benefits from these treatments costing in excess of 100'000 CHF per patient. Adiposs is developing a disruptive first-in-class product for detection of brown fat in cancer patients called ImageBAT. ImageBAT is a simple drink that patients take before their regular follow-up medical scan and predicts the response to immunotherapy. It's simple, fast, and pain-free. Cancer patients are spared the "trial and error" approach of cancer treatment and get a better chance to survive.